Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System
Impediments to biosimilar access prevent market competition from working properly, raise patient cost-sharing and harm long-term sustainability of biosimilar development. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 4, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today ’s Economy
These are the best blue-chip stocks for investors to consider Blue chip stocks are generally a strong investment for any stage of the economic cycle and tend to take advantage of overarching trends. That remains as true today as it was yesterday and will be tomorrow. Today’s economy is marked by a…#openai #nvidia #h100 #h200 #nvda #pfas #3m #abbvie #humira #rinvoq (Source: Reuters: Health)
Source: Reuters: Health - November 30, 2023 Category: Consumer Health News Source Type: news
Samsung Bioepis Marks a New Chapter in the Biosimilar Industry with Groundbreaking Advancements, Exclusive Interview by Xtalks
In an interview by Xtalks, company leaders at Samsung Bioepis, Ilsun Hong and Thomas Newcomer, discuss the company's advancements in the biosimilar industry. They discuss the FDA approval for both high- and low-concentration formulations of their adalimumab biosimilar and the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 29, 2023 Category: Pharmaceuticals Tags: PDT Source Type: news
3 Rising Stars: Invest Now in Tomorrow ’s Trillion-Dollar Companies
As the global economic landscape evolves, identifying burgeoning companies with potential to scale into trillion-dollar entities is a pursuit that captivates investors worldwide. In the realm of pharmaceuticals, technology, and semiconductor manufacturing, three standout enterprises are reshaping…#abbvie #humira #skyrizirinvoqvraylar #botox #rinvoq #crohn #usinternational #abbv #eps #tsmc (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2023 Category: Consumer Health News Source Type: news
The Best 7 Dividend Stocks to Own in Retirement
While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S. government to provide for your needs is not the best idea. The full retirement age is 66 if you were born between 1943 and 1954. The full retirement age increases gradually if you were born between…#abbvie #abbvieinc #abbottlaboratories #humira #allerganplc #allergan #botox #chevron #chevroncorporation #cvx (Source: Reuters: Health)
Source: Reuters: Health - November 19, 2023 Category: Consumer Health News Source Type: news
7 High-Yield Blue Chips Suitable for Any Retiree
High-yield blue-chip stocks are appropriate for every retirement portfolio Before extolling the benefits of high-yield blue-chip stocks, it’s important to acknowledge the reality that many investors are feeling. Long-term stock investors have had to muddle through challenging macroeconomic…#abbvie #humira #rinvoq #abbv #dividendking #johnsonjohnson #jnj #dukeenergy #duke #florida (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2023 Category: Consumer Health News Source Type: news
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA ™…
sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued group • Filing acceptance reinforces Samsung Bioepis and Organon's commitment to provide better…#phase4 #humira #samsungbioepis #organon #incheon #jerseycity #samsungbioepiscoltd #organonco #ogn #fda (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2023 Category: Consumer Health News Source Type: news
AbbVie (NYSE:ABBV) Exceeds Q3 Expectations; Hikes Dividend - TipRanks.com
Pharmaceutical behemoth AbbVie (NYSE:ABBV) delivered a better-than-anticipated third-quarter performance, with EPS of $2.95 outpacing expectations by $0.08. Revenue of $13.93 billion also fared better than the consensus by $220 million, despite a year-over-year decline of 5.9%. During the quarter,…#eps #immunology #humira #skyrizi #rinvoq #abbviesoncology #imbruvica #vraylar #ubrelvy #botox (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
AbbVie Lifts Profit Outlook as Newer Biologics Help Buffer Dwindling Humira Sales
(Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
AbbVie raises profit forecast after Humira, newer drugs drive results beat
The logo for AbbVie is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights Oct 27 (Reuters) - AbbVie (ABBV.N) on Friday raised its annual profit forecast after beating quarterly…#abbvie #newyorkcity #humira #sandoz #amgen #boehringeringelheim #rinvoq #imbruvica (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
FDA OKs Ninth Humira Biosimilar, With Interchangeability FDA OKs Ninth Humira Biosimilar, With Interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news
FDA Grants Interchangeable Designation to Pfizer ’s Biosimilar Abrilada
NEW YORK, October 5, 2023– Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). The... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 5, 2023 Category: Drugs & Pharmacology Source Type: news
CVS Joins Race to Sell Cheaper,'Biosimilar' Drugs
CVS will start selling less expensive, "biosimilar" versions of certain prescription medications, starting with its own version of Humira early next year, the drugstore chain said this week. The company is focusing on cheaper versions of biologic medications, a type of drug that's made from living…#cvs #humira #botox #sandoz #ameetsarpatwari #harvardmedicalschool #markcuban #premshah #biosimilar #fda (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2023 Category: Consumer Health News Source Type: news
CVS Health Launches Company To Produce Cheaper ‘Biosimilar’ Versions Of Expensive Biotech Drugs
CVS Health is launching a new company that will work directly with drug makers to produce and commercialize “biosimilar” drugs, the less expensive versions of expensive brand prescriptions derived from biotechnology. The new of the new company, Cordavis, will operate as “a wholly owned subsidiary…#cvshealth #cordavis #cvs #fda #humira (Source: Reuters: Health)
Source: Reuters: Health - August 23, 2023 Category: Consumer Health News Source Type: news
CVS pushes into making cheaper versions of complex drugs with new discount Humira
CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira that will sell for 80% below the price of the brand-named drug. The move is part of the company's new venture focused on securing, and in some cases co-producing,…#cvshealth #sandoz #humira #premshah #cvshealthevp #cvs #redoak #cardinalhealth #cordavis #novartis (Source: Reuters: Health)
Source: Reuters: Health - August 23, 2023 Category: Consumer Health News Source Type: news
